Obesity Pillars最新文献

{"title":"Nutritional status with tirzepatide in obesity: A post hoc analysis of the SURMOUNT-1-4 randomized clinical trials","authors":"Jaime P. Almandoz ,&nbsp;Octavia Pickett-Blakely ,&nbsp;Colleen Tewksbury ,&nbsp;Adam Stefanski ,&nbsp;Sylvia Gonsahn-Bollie ,&nbsp;Georgios K. Dimitriadis ,&nbsp;Ada Leticia Murro ,&nbsp;Dachuang Cao ,&nbsp;Qier Meng ,&nbsp;Lisa M. Neff","doi":"10.1016/j.obpill.2026.100248","DOIUrl":"10.1016/j.obpill.2026.100248","url":null,"abstract":"<div><h3>Background</h3><div>Nutritional deficiencies are common among people with obesity, before and during treatment, such as with very-low-calorie diets and metabolic/bariatric surgery. Obesity management medications (OMMs) can reduce appetite and dietary intake, potentially affecting nutritional status. The impact of OMMs on nutritional outcomes in people with obesity warrants further study.</div></div><div><h3>Methods</h3><div>We conducted a post hoc analysis of available nutritional status-related data from the randomized, placebo-controlled, phase 3 SURMOUNT-1-4 trials of tirzepatide (N = 4726). Descriptive statistics were utilized to explore available nutritional status-related data from clinical trial reports, including investigator-reported treatment-emergent adverse events (TEAEs) based on 14 <em>MedDRA</em> preferred terms, chosen to identify cases of macronutrient malnutrition; investigator-reported vitamin deficiency-related TEAEs; biomarkers assessed systematically during the trials (albumin; total lymphocyte count [TLC]); reasons for early treatment discontinuation; and participants reaching body mass index (BMI) &lt; 18.5 and &lt; 22 kg/m².</div></div><div><h3>Results</h3><div>Investigators reported 3 of 14 TEAEs potentially related to macronutrient malnutrition. TEAE incidence of <em>Abnormal loss of weight</em>, <em>Underweight</em>, and <em>Hypoalbuminemia</em> was 0.03 %, 0.06 %, and 0.03 % with tirzepatide and 0 %, 0 %, and 0.06 % with placebo, respectively. Vitamin deficiency-related TEAEs were reported for 0.99 % and 1.07 % of tirzepatide- and placebo-treated participants, respectively. Albumin &lt;3.3 g/dL occurred in 0.06 % and 0.13 % of tirzepatide- and placebo-treated participants, respectively, while TLC &lt;910/μL occurred in 2.90 % and 1.77 %. Treatment discontinuations potentially related to nutritional status (primarily achievement of desired weight and perceived excessive weight loss) occurred in 0.53 % of participants. Overall, 0.38 % and 0.06 % of tirzepatide- and placebo-treated participants reached BMI &lt;18.5 kg/m².</div></div><div><h3>Conclusions</h3><div>TEAEs and treatment discontinuations due to macronutrient malnutrition were uncommon in the SURMOUNT-1-4 trials of tirzepatide for obesity. Lack of routinely collected vitamin and mineral levels during the trials limited assessment of the impact of tirzepatide treatment on micronutrient status. Systematic assessment of nutritional status before and during OMM treatment would enhance future trials.</div></div><div><h3>Clinicaltrials.gov identifiers</h3><div>NCT04184622 (SURMOUNT-1); NCT04657003 (SURMOUNT-2); NCT04657016 (SURMOUNT-3); and NCT04660643 (SURMOUNT-4).</div></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"17 ","pages":"Article 100248"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146077173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weight reduction and treatment adherence with tirzepatide using the Individualized Virtual Integrative Medicine (IVIM) protocol","authors":"Jessica Duncan,&nbsp;Patrick Lee Stevens,&nbsp;Emily Bigby,&nbsp;Courtney Floyd,&nbsp;Josh Malina,&nbsp;Jennifer Nickens,&nbsp;Amber Lambert,&nbsp;Taylor Kantor","doi":"10.1016/j.obpill.2025.100236","DOIUrl":"10.1016/j.obpill.2025.100236","url":null,"abstract":"<div><h3>Introduction</h3><div>Obesity and its downstream effects continue to drive rising rates of chronic disease. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has shown significant potential in supporting weight loss and improving metabolic health. This study examines the use of tirzepatide alongside the Individualized Virtual Integrative Medicine (IVIM) protocol. This is a telehealth-based approach to improving outcomes through consistent access to care and support throughout the weight reduction journey.</div></div><div><h3>Methods</h3><div>This is a retrospective analysis of 1166 patients who completed at least 52-weeks of the IVIM clinical protocol while on GLP-1 therapy with tirzepatide overseen by a team of board-certified obesity medicine physicians and nurse practitioners. Only patients with a body mass index (BMI) of 30 or greater were included. Due to the branded tirzepatide shortage, patients were provided with the ability to utilize compounded tirzepatide medications, if medically appropriate.</div></div><div><h3>Results</h3><div>Mean change at 12-weeks for patients both on compounded tirzepatide and branded tirzepatide was −20.12 lbs (−8.80 %), 24-weeks: −35.67 lbs (−15.72 %), 36-weeks: −47.33 lbs (−20.34 %), 52-weeks: −52.28 lbs (−22.74 %). At 72 weeks of therapy, patients had lost an average of −62.79 lbs (−26.54 %). The percentage of patients who lost at least 5 % of their body weight at 52 weeks was: 99.36 %, 10 % or more: 97.12 %, 15 % or more: 84.66 %, 20 % or more: 64.22 %, and 25 % or more: 41.21 %.</div></div><div><h3>Discussion</h3><div>Patients completing 52-weeks of tirzepatide therapy on the IVIM protocol experienced significant weight loss with a high level of treatment adherence and program utilization. The findings suggest that individualized dose titration and frequent access to support may improve outcomes of patients initiated on weight reduction therapy with GLP-1 medications. These findings support the IVIM protocol as a safe, effective and individualized model for delivering obesity treatment through a curated, patient-centered, virtual approach.</div></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"17 ","pages":"Article 100236"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145694477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Ethiopian Orthodox Tewahedo Christian fasting on appetite hormones and insulin sensitivity in type-II diabetes and healthy subjects in Ethiopia","authors":"Alemayehu Michael ,&nbsp;Kaleab Baye","doi":"10.1016/j.obpill.2025.100226","DOIUrl":"10.1016/j.obpill.2025.100226","url":null,"abstract":"<div><h3>Background</h3><div>Energy restriction, time-restricted feeding, and vegetarian diet intake each have been linked independently to positive health effects. However, little is known about the religious fasts practiced by Ethiopian Orthodox Tewahedo Christians (EOTC) fasting, which combine energy restriction, time-restricted feeding, and vegetarian diet consumption.</div></div><div><h3>Method</h3><div>This longitudinal study compared the effects of EOTC fasting on appetite hormones, insulin sensitivity, and β-cell function. The fasting cohort comprised both individuals with diabetes and healthy individuals, and was compared against a non-fasting cohort that also included both individuals with diabetes and healthy individuals. We employed pretested structured questionnaire to collect information on fasting patterns, physical activity, and sociodemographic traits. Body weight was measured using an adult digital electronic scale (ASTO), and hormone activity was determined using enzyme-linked immunosorbent assay (ELISA) analyzer.</div></div><div><h3>Results</h3><div>EOTC fast significantly lower serum level of appetite hormones like glucagon (p &lt; 0.0001, p = 0.001), leptin (p = 0.002, p = 0.046) in both type-II diabetes and healthy subjects respectively compared to non-fasting. Insulin increased significantly (p = 0.002) in people with diabetes while decreased (p = 0.003) in healthy subjects. The concentration of ghrelin (p = 0.030) increased significantly in type-II diabetes but insignificantly (p = 0.135) in healthy subjects when compared to non-fasting. Both fasting people with diabetes and healthy subjects showed significant (p = 0.03, 0.010) improvements in insulin sensitivity and β-cell function respectively.</div></div><div><h3>Conclusion</h3><div>Concurrent vegetarian diet and energy restriction practiced among EOTC fasting may improve body weight managements. EOTC fasting improves activities of appetite hormones, increase insulin sensitivity and β-cell function (HOMA-IR) in both people with diabetes and healthy subjects. EOTC fasting practice represents a promising, culturally-accepted, non-pharmacological strategy for diabetes prevention and management.</div></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"17 ","pages":"Article 100226"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145799722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New era in obesity medication access: A commentary","authors":"Harold Edward Bays","doi":"10.1016/j.obpill.2025.100244","DOIUrl":"10.1016/j.obpill.2025.100244","url":null,"abstract":"","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"17 ","pages":"Article 100244"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145976501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obesity medications and acquired hypothalamic obesity in adults: A two-case experience","authors":"Henry Lang ,&nbsp;Madisen F. Dorand ,&nbsp;Mahnooor Hassan ,&nbsp;Jesse R. Richards","doi":"10.1016/j.obpill.2026.100246","DOIUrl":"10.1016/j.obpill.2026.100246","url":null,"abstract":"<div><h3>Background</h3><div>Acquired hypothalamic obesity (HO) lacks well-described adult pharmacotherapy outcomes, creating a unique clinical challenge for providers tasked with the treatment of patients with hypothalamic obesity.</div></div><div><h3>Methods</h3><div>We conducted a retrospective chart review to evaluate clinical outcomes in two patients who developed hypothalamic obesity following treatment for tumors of the central nervous system. Medical records from the research center were systematically examined to identify individuals meeting criteria for acquired hypothalamic obesity, defined by significant weight gain associated with hypothalamic injury secondary to tumor therapy.</div></div><div><h3>Results</h3><div>Two individuals with acquired hypothalamic obesity were identified, both of whom achieved clinically significant weight loss taking tirzepatide with phentermine, and tirzepatide with phentermine/topiramate combination therapy. In case 1, the patient presented with cirrhosis, dyslipidemia, and transaminitis. Tirzepatide was initiated and escalated to 7.5 mg weekly, without weight response, prompting the addition of phentermine 8 mg daily. Dual therapy yielded 12.26 % weight loss over 7 months. In case 2, the patient presented with hypertension and obstructive sleep apnea (OSA). Tirzepatide 2.5 mg weekly combined with phentermine/topiramate was initiated. Tirzepatide was escalated to 5 mg, with phentermine/topiramate subsequently increased to 37.5/50 mg daily, producing 35.10 % weight loss over 11 months.</div></div><div><h3>Conclusion</h3><div>Tirzepatide-based combination therapy was associated with clinically meaningful weight loss and comorbidity improvement in adults with HO. These cases support further study of targeted, multimodal regimens in patients with acquired HO.</div></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"17 ","pages":"Article 100246"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146037250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reporting the effectiveness of dietary intervention on weight loss outcomes in patients with obesity and overweight: a retrospective chart review at a Center of Excellence in UAE","authors":"Mona Joumaa ,&nbsp;Madeeha Kalsekar ,&nbsp;Momina Malik ,&nbsp;Fatemeh Akbarpoor ,&nbsp;Dana Abdelrahim ,&nbsp;Sara El Ghandour","doi":"10.1016/j.obpill.2025.100241","DOIUrl":"10.1016/j.obpill.2025.100241","url":null,"abstract":"<div><h3>Background</h3><div>A modest weight loss of ≥5 % among patients with obesity is associated with a reduced risk of type 2 diabetes, hypertension, and other obesity-related complications. Dietary interventions play a central role in obesity management and improving metabolic health, yet region-specific data from the United Arab Emirates (UAE) remains limited.</div></div><div><h3>Methods</h3><div>This retrospective chart review aims to assess effectiveness of dietary intervention on weight loss outcomes in patients with overweight and obesity attending a Center of Excellence for Weight Reduction and Obesity Management in UAE. This study included adult patients with BMI ≥25 kg/m² who received individualized dietary counseling between September 2018 and September 2021. Patients who had undergone bariatric procedures or on obesity medications were excluded. Anthropometric and body composition data were collected before and after intervention. Outcomes included changes in weight, BMI, fat mass, visceral fat, and other metabolic parameters. Statistical analyses included paired t-tests, correlation coefficients, and multivariate regression to assess associations between intervention frequency, duration, and weight-related outcomes.</div></div><div><h3>Results</h3><div>A total of 266 patients (mean age 44.46 ± 8.18 years; 63.9 % female) were included. Following the intervention, participants achieved significant mean weight loss of 5.12 % (p &lt; 0.001), with corresponding reductions in BMI (4.93 %, p &lt; 0.001), fat mass (10.11 %, p &lt; 0.001), and visceral fat (34.34 %, p = 0.014). More frequent sessions and longer follow-up durations were significantly associated with greater improvements in BMI, fat mass, and fat percentage. Gender-based analysis revealed that males experienced greater reductions in fat mass and resting energy expenditure compared to females.</div></div><div><h3>Conclusion</h3><div>The dietary intervention resulted in significant improvements in anthropometric and body composition indices. These findings support the efficacy of individualized, dietitian-led interventions in managing obesity. The observed gender differences highlight the importance of tailored approaches in obesity care. This study contributes to the limited body of evidence on effective, non-pharmacological obesity management strategies in UAE.</div></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"17 ","pages":"Article 100241"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145747898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical review of how glucagon-like peptide-1 agonist obesity medications decrease sexual desire, and a biopsychosocial model for why we don’t ‘see’ it","authors":"Sonya T. Gelfand ,&nbsp;Meghan C. Tveit ,&nbsp;James A. Simon","doi":"10.1016/j.obpill.2025.100233","DOIUrl":"10.1016/j.obpill.2025.100233","url":null,"abstract":"<div><h3>Background</h3><div>While prevailing assumptions suggest that improved body image and erectile function, even in people with diabetes, associated with glucagon-like peptide-1 (GLP-1) agonist medications would correlate with heightened sexual function, there is limited literature on the effects of GLP-1 agonists on hedonistic pleasures such as sexual activity. In this paper, we aim to elucidate the potential implications of GLP-1 agonists on sexual desire by proposing a serotonergic mechanism by which GLP-1 agonists theoretically decrease sexual desire, and a biopsychosocial perspective on why this effect may be camouflaged by competing influences.</div></div><div><h3>Methods</h3><div>This was a narrative review analysis with target literature search. A PubMed search was conducted to identify systematic reviews or meta-analyses investigating the effects of GLP-1 agonists on physiological and lifestyle factors. We used the same methodology to investigate the connection between GLP-1 agonism and the brain’s reward pathways to elucidate whether a connection exists between GLP-1 agonism and sexual desire.</div></div><div><h3>Results</h3><div>We established a theoretical model for how GLP-1 agonist modulation via increased serotonergic activity at the 5-HT2C receptor may result in diminished sexual desire. We then applied a biopsychosocial framework to highlight why this effect may be overlooked by GLP-1-treated patients and clinicians. Although the serotonergic pathway may create a physiological decrease in sexual desire for patients taking GLP-1 agonists, we postulate that this diminishing influence of GLP-1 agonism is both compounded by factors such as undesirable side effects and increased SHBG and offset by the enhancing influences on sexual desire such as increased total testosterone, and improved vascular reactivity and mood.</div></div><div><h3>Conclusion</h3><div>Failing to systematically measure and report on sexual desire as a potential adverse outcome of GLP-1 agonist use overlooks an essential aspect of patient well-being. Future research should prioritize longitudinal studies to assess changes in sexual desire among individuals prescribed GLP-1 agonists.</div></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"17 ","pages":"Article 100233"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145625393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1 - based therapies: An expert consensus statement using a modified Delphi approach","authors":"J.L. Sievenpiper ,&nbsp;J. Ard ,&nbsp;M. Blüher ,&nbsp;W. Chen ,&nbsp;J.B. Dixon ,&nbsp;A. Fitch ,&nbsp;L. Gigliotti ,&nbsp;K. Khunti ,&nbsp;A. Lecube ,&nbsp;M.E.J. Lean ,&nbsp;B. Mittendorfer ,&nbsp;A.F.H. Pfeiffer ,&nbsp;D.H. Ryan ,&nbsp;T. Vilsbøll ,&nbsp;L.F. Van Gaal","doi":"10.1016/j.obpill.2025.100228","DOIUrl":"10.1016/j.obpill.2025.100228","url":null,"abstract":"<div><h3>Background</h3><div>Liraglutide, semaglutide and tirzepatide have transformed the management of obesity. However, dose-related gastrointestinal effects, obesity-associated nutritional insufficiencies, and poor long-term adherence may limit their long-term health benefits. Despite a recent joint advisory summarizing nutritional and lifestyle supportive care priorities with these therapies, there is still a significant lack of direct evidence to guide clinical practice, making consensus-based recommendations necessary.</div></div><div><h3>Methods</h3><div>The consensus statement development was based on an initial scoping review that included searching PubMed, Embase, Web of Science, Cochrane, and Medline for relevant scientific publications from January 1, 2021 through June 30, 2025. An international multidisciplinary panel consisting of physicians, clinical researchers, and dietitians employed a modified Delphi process to develop clinical practice recommendations for nutritional and lifestyle strategies that may assist people on glucagon-like peptide 1 based therapies (GBT) in optimizing treatment experience and improving health outcomes.</div></div><div><h3>Results</h3><div>A total of 52 consensus statements were developed, outlining key considerations for the practical management of obesity and associated complications with GBTs, with a focus on nutritional factors in relation to obesity, body composition, physical activity, and the management of common gastrointestinal symptoms such as nausea, vomiting, diarrhoea, and constipation. The consensus statements include practical strategies supporting the weight loss journey, from before starting a GBT, during the weight loss and weight maintenance phases, and in case of GBT discontinuation. The statements were primarily derived from indirect evidence, including from existing evidence and established guidelines for nutrition therapy in bariatric medicine and relevant clinical experience.</div></div><div><h3>Conclusions</h3><div>These expert consensus recommendations offer healthcare professionals practical guidance on nutritional and lifestyle interventions for patients undergoing GBT-related weight management, complementing current recommendations. Further direct evidence is urgently required to inform and enhance optimal clinical care.</div></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"17 ","pages":"Article 100228"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145799725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Logistics, effectiveness, safety, and accessibility: Factors determining obesity medication patient preferences from a photovoice analysis","authors":"Alvin Mondoh ,&nbsp;Francisca Contreras ,&nbsp;Hilary Craig ,&nbsp;Michael Crotty ,&nbsp;Carel W. le Roux","doi":"10.1016/j.obpill.2025.100238","DOIUrl":"10.1016/j.obpill.2025.100238","url":null,"abstract":"<div><h3>Background</h3><div>Obesity is a chronic, relapsing, and multifactorial disease that necessitates sustained, patient-centred management. Although pharmacotherapy is now an integral component of obesity care, there is limited evidence regarding the factors influencing patients’ choices among specific medications. As part of the Innovative Medicines Initiative 2 (IMI2) programme. Stratification of Obesity Phenotypes to Optimize Future Obesity Therapy (SOPHIA) and the second phase of a three-part qualitative doctoral programme, the present study is built upon previous interview findings that examined how patients conceptualize and interpret the factors shaping their pharmacotherapy preferences.</div></div><div><h3>Methods</h3><div>A qualitative Photovoice methodology was employed with treatment naive adults attending a specialist weight management clinic. Participants captured photographs reflecting factors shaping their medication choices and they also engaged in facilitated reflective interviews. Data was analysed using the MAXQDA 2024 software and the Braun and Clarke's framework for reflexive thematic analysis.</div></div><div><h3>Results</h3><div>The photovoice analysis revealed 4 themes around patient preferences for obesity medications including a) Logistics around Lifestyle, b) Effectiveness, c) Safety, risk and tolerability and d) Accessibility.</div></div><div><h3>Conclusion</h3><div>Patient preferences for obesity pharmacotherapy arise from the interaction of efficacy expectations with logistical challenged, while concerns regarding safety and accessibility also contribute to decision making. Clinicians should include explanations how the medications can fit into the lifestyle of patients, while also addressing structural barriers that may affect access to treatment, but ultimately allowing patients to understand the balance between efficacy and safety will allow optimal shared decision-making to support sustainable pharmacotherapy pathways.</div></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"17 ","pages":"Article 100238"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145694478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving nutritional assessment in GLP-1RA therapy: Beyond self-reports to equitable interventions","authors":"Parth Aphale,&nbsp;Himanshu Shekhar,&nbsp;Shashank Dokania","doi":"10.1016/j.obpill.2025.100213","DOIUrl":"10.1016/j.obpill.2025.100213","url":null,"abstract":"","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"16 ","pages":"Article 100213"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145227022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}